Covidien launches the Swift prime study, 1 of the largest studies to examine acute ischemic stroke.
Covidien (NYSE:COV) enrolled the 1st patient in the Swift Prime study, a multi-center, randomized, controlled trial of its Solitaire FR revascularization device for restoring blood flow to the brain.
Medical device maker launches commercial sales of its OneShot renal denervation system in Europe, Middle East, Africa, Asia and Latin America.
Medical device maker Covidien (NYSE:COV) this week announced commercial launch of its OneShot renal denervation system in markets around the world, bringing the company up to speed with some of its renal denervation rivals.
Wall Street investors send shares of St. Jude Medical up yesterday and down today after the company reveals a warning letter from the FDA over its Sylmar, Calif., Durata defibrillator lead plant.
A warning letter from the FDA to St. Jude Medical (NYSE:STJ) sent the St. Paul, Minn.-based medical device company's stock on a seesaw ride yesterday and today.
STJ shares closed up 1.5% yesterday at $38.85 each after St. Jude revealed the warning letter, but closed down 1.2% today at $38.39 apiece.
Covidien corporate communications and public relations senior vice president Eric Kraus takes a role at Bacardi Limited, the largest privately held spirits company in the world.
Covidien (NYSE:COV) corporate communications and public relations senior vice president Eric Kraus will leave his post by the end of this month to take on a role as the communications chief for Bacardi Limited, the worlds largest privately owned spirits company.
MassDevice.com looks at the internet chatter surrounding the medical device industry with some of most searched-for companies of 2012.
The medical device industry was full of big stories in 2012, ranging from efforts to bring down the device tax and related layoffs to epic public face-offs between industry leaders.
Covidien releases 5- year results of its ClosureFast Long-Term European Multi-Center Study in treating patients with chronic venous insufficiency.
Covidien (NYSE:COV) unveiled the results of its ClosureFast Long-Term European Multi-Center Study, which evaluated 5-year outcomes of the medical device maker's radiofrequency ablation therapy in patients with chronic venous insufficiency.
Medical devices made a lot of headlines in 2012, and the word "layoffs" was in many of them.
The medical device industry had a lot of big stories during the last year, including tales of recalls, lawsuits and CEO swapping, but the single factor that drove more big headlines than any other was news of layoffs.
Some of the biggest companies in the industry announced significant cuts in 2012, amounting to about 7,000 reported layoffs, by some estimates.